GDF15 analogs as obesity therapeutics

Samuel N Breit; David A Brown; Vicky Wang Wei Tsai

doi:10.1016/j.cmet.2023.01.002

GDF15 analogs as obesity therapeutics

Cell Metab. 2023 Feb 7;35(2):227-228. doi: 10.1016/j.cmet.2023.01.002.

Authors

Samuel N Breit¹, David A Brown², Vicky Wang Wei Tsai³

Affiliations

¹ St. Vincent's Centre for Applied Medical Research, St. Vincent's Hospital, Sydney and University of New South Wales, Sydney, NSW 2010, Australia. Electronic address: s.breit@unsw.edu.au.
² Department of Immunopathology, Institute for Clinical Pathology and Medical Research-New South Wales Health Pathology, Westmead Hospital, Sydney, NSW, Australia.
³ St. Vincent's Centre for Applied Medical Research, St. Vincent's Hospital, Sydney and University of New South Wales, Sydney, NSW 2010, Australia.

PMID: 36754014
DOI: 10.1016/j.cmet.2023.01.002

Abstract

There is increasing interest in GDF15 analogs as therapeutic agents for obesity. In this issue of Cell Metabolism, Benichou et al. report the first clinical trial of such a drug in obese humans.

Publication types

Comment

MeSH terms

Growth Differentiation Factor 15*
Humans
Obesity* / drug therapy
Obesity* / metabolism

Substances

GDF15 protein, human
Growth Differentiation Factor 15